Loading company…
Lyvgen Biopharma develops monoclonal antibody immuno-oncology therapies that activate the immune response against tumors.
Founded in 2016 and based in Shanghai, China, Lyvgen Biopharma Co., Ltd develops immuno-oncology therapeutics using its xLinkAb platform. Its monoclonal antibodies, including LVGN6051, LVGN7409 and LVGN3616, aim to activate antitumor immune responses or block the PD-1 pathway. The company raised USD 30.00 mn in a Series B round on February 23, 2021, and Jieyi Wang is CEO. It is at Series C stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in